Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German company launches "age scan" machine:

This article was originally published in Clinica

Executive Summary

With the help of the Technical University of Munich, the German medical equipment manufacturer Ant.Ox has developed a device designed to assess a person's biological age. The machine performs four examinations containing a total of 24 parameters covering an age scan, a bone scan, a hormonal scan and an "oxidative stress" test. It incorporates touch-screen programming, a high capability computer and an infrared interface for data transfer. Dr Andreas Fromer of Ant-ox said: "The machine is targeted at manager-types between the ages of 35-45 who want to monitor their health levels. We envisage that it will be useful to private practices, fitness centres and plastic surgeons. Information gathered can then be taken to a doctor." The machine is available at a cost of DM34,900 ($15,052), with each individual scan costing DM250.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel